BeiGene Cash Flow from Investing Activities 2014-2024 | ONC
BeiGene annual/quarterly cash flow from investing activities history and growth rate from 2014 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- BeiGene cash flow from investing activities for the quarter ending September 30, 2024 was $-0.455B, a 470.95% decline year-over-year.
- BeiGene cash flow from investing activities for the twelve months ending September 30, 2024 was $-0.925B, a 152.89% decline year-over-year.
- BeiGene annual cash flow from investing activities for 2023 was $0.06B, a 94.43% decline from 2022.
- BeiGene annual cash flow from investing activities for 2022 was $1.077B, a 68.13% increase from 2021.
- BeiGene annual cash flow from investing activities for 2021 was $0.641B, a 120.22% decline from 2020.
BeiGene Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$60 |
| 2022 |
$1,077 |
| 2021 |
$641 |
| 2020 |
$-3,168 |
| 2019 |
$554 |
| 2018 |
$-638 |
| 2017 |
$-356 |
| 2016 |
$-222 |
| 2015 |
$-59 |
| 2014 |
$-34 |
| 2013 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
